Insect-derived bioactives for sustainable functional food development: evidence, limitations and translational insights from established natural sources
- 1Corresponding author.
- 2School of Biotechnology, Life Science Institute, Dublin City University, D9, Dublin, Ireland
Abstract
With the population growing at a rapid rate and resource availability a constant challenge, future sustainable food production is of critical importance. In this review, we highlight the importance of natural resources in functional-food development and as sources of health-related bioactive compounds. We examine how insect-derived functional foods and bioactives may contribute to research on inflammatory bowel disease and gut health, viral infection, cancer, cardiovascular health and obesity, using milk-derived, microbial, fungal, plant and marine bioactives as established translational reference points. Across these areas, insect-derived materials have demonstrated effects on inflammatory signalling, intestinal barrier function, viral replication, apoptosis, cardiovascular-related pathways, lipid metabolism and the gut microbiota. However, most evidence is derived from in vitro and animal studies, with very limited human evidence. Mechanistic confidence is greater for defined compounds and characterised fractions than for whole-insect powders or crude extracts, for which the active component and relevant dose are often uncertain. Comparison with established natural sources highlights recurring limitations in compound characterisation, evidence strength, reproducibility, safety, bioavailability and clinical translation. Insects therefore represent a promising and sustainable source of functional-food ingredients and candidate bioactive compounds; however, the current evidence does not support their use as established treatments for human disease without further investigation.
Related
- Food-Derived Bioactives and the Endothelial Glycocalyx: Chemical Determinants, Molecular Mechanisms, and Translational Evidence
- Protective effects of icariin in atherosclerotic cardiovascular disease: mechanistic basis, post-ischemic protection and translational limitations
- Micronized Bone Marrow and Niche Preservation: Biological Rationale, Preclinical Evidence, Translational Potential and Limitations
- Trained immunity in cancer immunotherapy and vaccine development: mechanisms, evidence gaps, and translational opportunities
- Direct regulation of a tRNA modification enzyme by ppGpp links stress signaling to translational control and biofilm development
BibTeX
@article{finnegan2026insectderived,
title = {{Insect-derived bioactives for sustainable functional food development: evidence, limitations and translational insights from established natural sources}},
author = {Dearbhla Finnegan and Christine Loscher},
journal = {Future Foods},
year = {2026},
month = oct,
doi = {10.1016/j.fufo.2026.101226},
url = {https://doi.org/10.1016/j.fufo.2026.101226},
note = {CC BY},
}
RIS
TY - JOUR
TI - Insect-derived bioactives for sustainable functional food development: evidence, limitations and translational insights from established natural sources
AU - Dearbhla Finnegan
AU - Christine Loscher
PY - 2026
DA - 2026/10/30
JO - Future Foods
DO - 10.1016/j.fufo.2026.101226
UR - https://doi.org/10.1016/j.fufo.2026.101226
AB - With the population growing at a rapid rate and resource availability a constant challenge, future sustainable food production is of critical importance. In this review, we highlight the importance of natural resources in functional-food development and as sources of health-related bioactive compounds. We examine how insect-derived functional foods and bioactives may contribute to research on inflammatory bowel disease and gut health, viral infection, cancer, cardiovascular health and obesity, using milk-derived, microbial, fungal, plant and marine bioactives as established translational reference points. Across these areas, insect-derived materials have demonstrated effects on inflammatory signalling, intestinal barrier function, viral replication, apoptosis, cardiovascular-related pathways, lipid metabolism and the gut microbiota. However, most evidence is derived from in vitro and animal studies, with very limited human evidence. Mechanistic confidence is greater for defined compounds and characterised fractions than for whole-insect powders or crude extracts, for which the active component and relevant dose are often uncertain. Comparison with established natural sources highlights recurring limitations in compound characterisation, evidence strength, reproducibility, safety, bioavailability and clinical translation. Insects therefore represent a promising and sustainable source of functional-food ingredients and candidate bioactive compounds; however, the current evidence does not support their use as established treatments for human disease without further investigation.
SN - 2666-8335
ER -